Atossa Therapeutics (Nasdaq:ATOS) - Aandelenkoers, Nieuws & Analyse

ATOS Overzicht aandelen

ATOS fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Atossa Therapeutics, Inc. Concurrenten

Achieve Life Sciences

NasdaqCM:ACHV

US$147.5m

Gossamer Bio

NasdaqGS:GOSS

US$157.6m

Sagimet Biosciences

NasdaqGM:SGMT

US$153.2m

Yumanity Therapeutics

NasdaqCM:YMTX

US$143.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Atossa Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$1.22
52 Week Hoogtepunt	US$2.31
52 Week Laag	US$0.70
Bèta	1.23
11 maand verandering	-14.08%
3 maanden verandering	-15.86%
1 Jaar Verandering	54.45%
33 jaar verandering	-46.49%
5 jaar verandering	-10.29%
Verandering sinds IPO	-99.86%

Recent nieuws en updates

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Nov 12

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Nov 08

Recent updates

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

Rendement voor aandeelhouders

	ATOS	US Biotechs	US Markt
7D	-4.7%	2.5%	2.2%
1Y	54.4%	16.1%	31.6%

Rendement versus industrie: ATOS overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 16.1 % opleverde.

Rendement versus markt: ATOS overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.6 %.

Prijsvolatiliteit

Is ATOS's price volatile compared to industry and market?
ATOS volatility
ATOS Average Weekly Movement	7.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: ATOS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van ATOS is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	12	Steve Quay	www.atossatherapeutics.com

Atossa Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt geneesmiddelen op het gebied van onbeantwoorde medische behoefte in de oncologie voor vrouwen borstkanker en andere aandoeningen in de Verenigde Staten. Het belangrijkste kandidaat-geneesmiddel van het bedrijf is oraal (Z)-endoxifen, een actieve metaboliet van tamoxifen, dat zich in Fase II van het klinisch onderzoek bevindt voor de behandeling en preventie van borstkanker. Het ontwikkelt ook immunotherapie/chimeric antigen receptor therapy programma's.

Atossa Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Atossa Therapeutics zich tot de beurswaarde?
ATOS fundamentele statistieken
Marktkapitalisatie	US$153.48m
Inkomsten(TTM)	-US$26.91m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-5.7x

Koers/Winstverhouding

Is ATOS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ATOS resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$26.91m
Inkomsten	-US$26.91m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.21
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ATOS op de lange termijn?

Bekijk historische prestaties en vergelijking

ATOS Overzicht aandelen

Risicoanalyse

Atossa Therapeutics, Inc. Concurrenten

NasdaqCM:ACHV

US$147.5m

NasdaqGS:GOSS

US$157.6m

NasdaqGM:SGMT

US$153.2m

NasdaqCM:YMTX

US$143.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target increased by 7.7% to US$5.83

New major risk - Revenue and earnings growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Recent updates

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target increased by 7.7% to US$5.83

New major risk - Revenue and earnings growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

New minor risk - Share price stability

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

New minor risk - Share price stability

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Price target decreased by 7.5% to US$4.63

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Price target decreased to US$5.00

Price target decreased to US$5.00

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics GAAP EPS of -$0.05